Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20805515 | 0.99 | CYP11B1 (0.35) | CYP11B1CYP11B2FEN1ALOX5APTNK2 | |
| SCHEMBL17486052 | 0.89 | DHODH (0.35) | GABRA1GABRB2SIGMAR1 | |
| SCHEMBL17486157 | 0.86 | PTGDR2 (0.33) | FEN1ALOX5AP | |
| SCHEMBL19295166 | 0.80 | ADORA2A (0.32) | CYP11B1CYP11B2FEN1ALOX5AP | |
| SCHEMBL17486170 | 0.76 | SIGMAR1 (0.39) | CYP11B1CYP11B2SIGMAR1 | |
| SCHEMBL17485992 | 0.75 | MEN1 (0.40) | — | |
| SCHEMBL17486224 | 0.74 | KDM1A (0.35) | SIGMAR1 | |
| SCHEMBL24088327 | 0.73 | GP6 (0.37) | GABRA1GABRB2 | |
| SCHEMBL19295168 | 0.72 | PPARA (0.33) | — | |
| SCHEMBL24088131 | 0.72 | GP6 (0.36) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | CYP11B1 2725/4885CYP11B2 2183/4885FEN1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.